<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Cipolat S</submitter><funding>Cancer Research UK</funding><funding>European Union</funding><funding>Medical Research Council</funding><funding>Wellcome Trust</funding><pagination>e01888</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4007207</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>3</volume><pubmed_abstract>Atopic dermatitis can result from loss of structural proteins in the outermost epidermal layers, leading to a defective epidermal barrier. To test whether this influences tumour formation, we chemically induced tumours in EPI-/- mice, which lack three barrier proteins-Envoplakin, Periplakin, and Involucrin. EPI-/- mice were highly resistant to developing benign tumours when treated with 7,12-dimethylbenz(a)anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA). The DMBA response was normal, but EPI-/- skin exhibited an exaggerated atopic response to TPA, characterised by abnormal epidermal differentiation, a complex immune infiltrate and elevated serum thymic stromal lymphopoietin (TSLP). The exacerbated TPA response could be normalised by blocking TSLP or the immunoreceptor NKG2</pubmed_abstract><journal>eLife</journal><pubmed_title>Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility.</pubmed_title><pmcid>PMC4007207</pmcid><funding_grant_id>096540</funding_grant_id><pubmed_authors>Watt FM</pubmed_authors><pubmed_authors>Natsuga K</pubmed_authors><pubmed_authors>Cipolat S</pubmed_authors><pubmed_authors>Hoste E</pubmed_authors><pubmed_authors>Quist SR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility.</name><description>Atopic dermatitis can result from loss of structural proteins in the outermost epidermal layers, leading to a defective epidermal barrier. To test whether this influences tumour formation, we chemically induced tumours in EPI-/- mice, which lack three barrier proteins-Envoplakin, Periplakin, and Involucrin. EPI-/- mice were highly resistant to developing benign tumours when treated with 7,12-dimethylbenz(a)anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA). The DMBA response was normal, but EPI-/- skin exhibited an exaggerated atopic response to TPA, characterised by abnormal epidermal differentiation, a complex immune infiltrate and elevated serum thymic stromal lymphopoietin (TSLP). The exacerbated TPA response could be normalised by blocking TSLP or the immunoreceptor NKG2</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014 May</publication><modification>2025-04-21T18:56:46.691Z</modification><creation>2019-03-27T01:27:26Z</creation></dates><accession>S-EPMC4007207</accession><cross_references><pubmed>24843010</pubmed><doi>10.7554/eLife.01888</doi></cross_references></HashMap>